Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

Objective The purpose of this 24‐month phase III study was to examine structural preservation
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …

Objective To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP‐690,550)
or adalimumab monotherapy with placebo for the treatment of active rheumatoid …

Objective To compare the efficacy, safety, and tolerability of 6 dosages of oral tofacitinib (CP‐690,550)
with placebo for the treatment of active rheumatoid arthritis (RA) in patients …

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib
versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or …

An understanding of the experience of food insecurity by children is essential for better
measurement and assessment of its effect on children's nutritional, physical, and mental health. …

Cognitive interviewing methods were used to adapt questions from the US Food Security
Survey Module for administration to children. Individual concurrent probing techniques using …

OBJECTIVE: To determine if measures of diet quality differ between food insecure and food
secure adults in a rural high-risk population. DESIGN: Random digit dialing telephone …

Objectives To evaluate malignancies and their associations with baseline risk factors and
cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in …